In Innovate in PA Tax Credit, further providing for legislative intent, for definitions, for duties, for use of tax credits by qualified taxpayers, for sale, carryover and carryback, for sale of tax credits to qualified taxpayers, for Innovate in PA Program, for guidelines and for report and providing for second distribution report.
SB1175 expands Pennsylvania’s Innovate in PA Tax Credit program by authorizing a new, larger round of tax credit sales and directing the proceeds to a broader set of innovation and workforce-development uses. The bill allows the Department of Revenue to sell up to $350 million in additional tax credits beginning October 1, 2026, with purchasers able to use those credits against insurance premiums tax liability beginning in 2030. It also sets a new annual cap of $70 million on credits applied against insurance premiums tax liability starting in calendar year 2030, and extends carryover rules for credits sold under the new authority through tax years beginning before December 31, 2034.
The bill revises the program’s legislative intent to emphasize investment in innovation, including life sciences, biotechnology, Ben Franklin Technology Partners, regional biotechnology research centers, workforce development, and venture capital. It also creates a “second distribution” of net proceeds from the new tax credit sale, allocating funds to the Commonwealth Financing Authority for commercial lab space and related facilities, to the Department of Revenue for recruitment and retention of life science researchers, to labor and education agencies for training and internship programs, to Ben Franklin Technology Partners, to the Venture Investment Program, and to regional biotechnology research centers. The bill adds a new annual reporting requirement detailing purchasers, allocations, investments, jobs created and retained, and participation in training programs.
The bill’s impact on state law is to amend multiple sections of the Tax Reform Code’s Innovate in PA article, expanding the scale and timing of tax credit sales and changing how proceeds are distributed and reported. It affects the Department of Revenue, the Commonwealth Financing Authority, the Department of Labor and Industry, the Department of Education, the Department of Human Services, Ben Franklin Technology Partners, venture investment administrators, regional biotechnology research centers, and qualified taxpayers purchasing the credits. It also creates new transparency obligations through annual public reporting.
Overall, the bill appears to have a pro-investment, pro-innovation orientation, with an emphasis on economic development, life sciences, and workforce pipeline building. Because no committee transcripts or votes were provided, there is no recorded public debate or voting history in the supplied materials to indicate broader legislative sentiment. Based on the text alone, the measure is structured as a targeted economic development expansion rather than a controversial tax increase or spending cut.
SB1175 amends the Tax Reform Code of 1971 to expand the Innovate in PA Tax Credit program, authorize up to $350 million in additional tax credit sales, extend carryover periods for the new credits, impose a new annual cap on credits used against insurance premiums tax liability, and establish a new distribution formula for proceeds. It also adds a new annual reporting section requiring detailed disclosure on credit purchasers, fund recipients, investments, job impacts, and program participation, thereby increasing administrative duties for the Department of Revenue and related agencies.
The bill’s text reflects a strongly supportive posture toward innovation-based economic development, especially in biotechnology and life sciences. It is framed as an investment in competitiveness, research infrastructure, workforce training, and venture capital. No committee discussion or vote data were provided, so there is no documented opposition or bipartisan split in the available record; the available materials suggest a generally favorable, development-oriented intent.
No committee transcripts or roll-call votes were provided, so no specific points of contention are documented in the supplied materials. Potential areas of debate suggested by the bill text include the size of the additional tax credit authorization, the use of insurance premiums tax liability as the offset, the allocation of proceeds among competing innovation and workforce programs, and the new reporting and transparency requirements. Any concerns would likely center on fiscal exposure, program effectiveness, and whether the distribution formula fairly balances research, training, and venture investment priorities.